[go: up one dir, main page]

FI4181920T3 - Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon - Google Patents

Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon

Info

Publication number
FI4181920T3
FI4181920T3 FIEP21749550.6T FI21749550T FI4181920T3 FI 4181920 T3 FI4181920 T3 FI 4181920T3 FI 21749550 T FI21749550 T FI 21749550T FI 4181920 T3 FI4181920 T3 FI 4181920T3
Authority
FI
Finland
Prior art keywords
inhibitor
kat6
pharmaceutically acceptable
acceptable salt
breast cancer
Prior art date
Application number
FIEP21749550.6T
Other languages
English (en)
Inventor
Paul Anthony Stupple
Anthony Mazurek
Kim Timothy Arndt
Lei Chen
Maximillian Todd Follettie
David Scott Fruhling
Pei-Pei Kung
Wenyan Zhong
Philip Michael Tedeschi
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Application granted granted Critical
Publication of FI4181920T3 publication Critical patent/FI4181920T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

PATENTTIVAATIMUKSET
1. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi menetelmässä syövän hoitamiseksi, jossa mainittu menetelmä käsittää mainitun lysiiniase- tyylitransferaasi 6:n (KAT6) estäjän määrän ja a) sykliiniriippuvaisen kinaasi 4:n (CDK4) es- täjän määrän; tai b) antiestrogeenin määrän; tai c) CDK4-estäjän määrän ja antiestrogeenin mää- rän antamisen sitä tarvitsevalle potilaalle; jossa määrät yhdessä ovat terapeuttisesti te- hokkaita syövän hoidossa; jossa syöpä on rintasvyöpä; jossa KAT6-estäjä on 2-metoksi-N-{4-metoksi- 6- [ (1H-pyratsol-1-vyli)metyyli]-1,2-bentsoksatsol-3- yylijbentseeni-1-sulfonamidi tai sen farmaseuttisesti hyväksyttävä suola; jossa antiestrogeeni on ful- vestrantti; ja jossa CDK4-estäjä on joko 1,5-anhydro-3-({5- kloori-4-[4-fluori-2-(2-hydroksipropan-2-yyli)-1-(pro- pan-2-yyli)-1H-bentsimidatsol-6-yylilpyrimidin-2- yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen far- maseuttisesti hyväksyttävä suola tai palbosiklibi tai sen farmaseuttisesti hyväksyttävä suola.
2. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi menetelmässä, jolla voitetaan klii- ninen resistenssi endokriinistä hoitoa vastaan, jossa mainittu menetelmä käsittää mainitun KAT6-estäjän ja CDK4-estäjän määrän antamisen sitä tarvitsevalle poti- laalle, jossa määrät yhdessä ovat terapeuttisesti te- hokkaita voittamaan kliinisen resistenssin endokrii- nistä hoitoa vastaan; jossa endokriinistä hoitoa käytetään rinta- syövän hoidossa;
jossa KAT6-estäjä on 2-metoksi-N-{4-metoksi- 6- [ (1H-pyratsol-1-vyli)metyyli]-1,2-bentsoksatsol-3- yylijbentseeni-1-sulfonamidi tai sen farmaseuttisesti hyväksyttävä suola; ja jossa CDK4-inhibiittori on joko 1,5-anhydro- 3- ( (5-kloori-4-[4-fluori-2-(2-hydroksipropan-2-vyvyli)- 1- (propan-2-yyli)-1H-bentsimidatsol-6-yylilpyrimidin- 2-yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen farmaseuttisesti hyväksyttävä suola tai palbosiklibi tai sen farmaseuttisesti hyväksyttävä suola.
3. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi patenttivaatimuksen 1 tai patentti- vaatimuksen 2 mukaisesti, jossa CDK4-estäjä on 1,5- anhydro-3- ( (5-kloori-4-[4-fluori-2-(2-hydroksipropan- 2-yyli)-1-(propan-2-yyli)-1H-bentsimidatsol-6-yylilpy- rimidin-2-yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen farmaseuttisesti hyväksyttävä suola.
4. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi patenttivaatimuksen 1 tai patentti- vaatimuksen 2 mukaisesti, jossa CDK4-estäjä on palbosi- klibi tai sen farmaseuttisesti hyväksyttävä suola.
5. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1-4 mu- kaisesti, jossa potilas on ihminen.
6. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1 tai 2 mukaisesti, jossa rintasyöpä on paikallisesti edennyt tai metastasoitunut estrogeenireseptoripositiivinen (ER+) rintasyöpä.
7. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1 tai 2 mukaisesti, jossa rintasyöpä on paikallisesti edennyt tai metastasoitunut estrogeenireseptoripositiivinen (ER+) ja ihmisen epidermaalisen kasvutekijän reseptori 2 -negatiivinen (HER2-) rintasvyöpä.
FIEP21749550.6T 2020-07-15 2021-07-15 Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon FI4181920T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052215P 2020-07-15 2020-07-15
US202163211044P 2021-06-16 2021-06-16
PCT/EP2021/069787 WO2022013369A1 (en) 2020-07-15 2021-07-15 Kat6 inhibitor methods and combinations for cancer treatment

Publications (1)

Publication Number Publication Date
FI4181920T3 true FI4181920T3 (fi) 2025-11-20

Family

ID=77179980

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21749550.6T FI4181920T3 (fi) 2020-07-15 2021-07-15 Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon

Country Status (18)

Country Link
EP (2) EP4667055A2 (fi)
JP (1) JP2022019654A (fi)
KR (1) KR20230058614A (fi)
CN (1) CN116113407A (fi)
AU (2) AU2021308406A1 (fi)
BR (1) BR112023000687A2 (fi)
CA (1) CA3189410A1 (fi)
DK (1) DK4181920T3 (fi)
ES (1) ES3050760T3 (fi)
FI (1) FI4181920T3 (fi)
HU (1) HUE073220T2 (fi)
IL (1) IL299871A (fi)
MX (1) MX2023000735A (fi)
PT (1) PT4181920T (fi)
SI (1) SI4181920T1 (fi)
TW (1) TW202216131A (fi)
WO (1) WO2022013369A1 (fi)
ZA (1) ZA202300875B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240140947A1 (en) * 2022-10-18 2024-05-02 Pfizer Inc. Compound for the treatment of cancer

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3137472A1 (en) 2019-04-25 2020-10-29 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
WO2023280182A1 (zh) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
AR127681A1 (es) 2021-11-16 2024-02-21 Insilico Medicine Ip Ltd Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos
AU2022400308B2 (en) * 2021-12-02 2026-02-12 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
JP2025511122A (ja) 2022-03-28 2025-04-15 アイソステリックス， インコーポレイテッド リジンアセチルトランスフェラーゼのｍｙｓｔファミリーの阻害剤
US20260027087A1 (en) 2022-07-29 2026-01-29 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
TW202440097A (zh) * 2023-03-27 2024-10-16 大陸商北京康辰藥業股份有限公司 磺醯胺化合物、其藥物組合物和用途
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
KR20250172879A (ko) * 2023-04-19 2025-12-09 인실리코 메디신 아이피 리미티드 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제, 그의 조합 및 용도
CN117448454B (zh) * 2023-10-30 2025-09-30 赣南医科大学 Kat6a在制备结直肠癌肝转移诊断试剂盒中的应用
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
EP2069344A2 (en) 2006-09-08 2009-06-17 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
ES2694787T3 (es) 2013-02-21 2018-12-27 Pfizer Inc. Formas sólidas de un inhibidor selectivo de CDK4/6
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
SG11201806251WA (en) * 2016-03-15 2018-08-30 Merrimack Pharmaceuticals Inc Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
GEAP202215475A (en) 2018-04-26 2022-07-11 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020055667A2 (en) 2018-09-10 2020-03-19 3M Innovative Properties Company Electrical power cable monitoring device including partial discharge sensor
CA3137472A1 (en) * 2019-04-25 2020-10-29 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
ES3043899T3 (en) * 2019-06-18 2025-11-26 Pfizer Benzisoxazole sulfonamide derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240140947A1 (en) * 2022-10-18 2024-05-02 Pfizer Inc. Compound for the treatment of cancer

Also Published As

Publication number Publication date
ES3050760T3 (en) 2025-12-22
PT4181920T (pt) 2025-11-04
EP4181920A1 (en) 2023-05-24
CA3189410A1 (en) 2022-01-20
CN116113407A (zh) 2023-05-12
IL299871A (en) 2023-03-01
JP2022019654A (ja) 2022-01-27
MX2023000735A (es) 2023-02-13
HUE073220T2 (hu) 2026-01-28
SI4181920T1 (sl) 2026-01-30
WO2022013369A1 (en) 2022-01-20
AU2025200238A1 (en) 2025-01-30
EP4667055A2 (en) 2025-12-24
DK4181920T3 (da) 2025-09-29
ZA202300875B (en) 2023-09-27
TW202216131A (zh) 2022-05-01
KR20230058614A (ko) 2023-05-03
BR112023000687A2 (pt) 2023-02-07
AU2021308406A1 (en) 2023-02-23
EP4181920B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
FI4181920T3 (fi) Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
Fnlay Pharmacokinetics of terbinafine in the nail
TWI454249B (zh) 用於治療或預防甲癬或足癬之壓敏膠黏劑基質藥貼裝置
JP2007529421A5 (fi)
ATE300262T1 (de) Allzweck -medikament und -wärmebehandlungssystem
DE50209721D1 (de) Screeningverfahren mit pim1-kinase oder pim3-kinase
MX2025004433A (es) Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer
BRPI0517976A (pt) métodos de tratamento
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
CN104083200B (zh) 一种骨科固定装置
MX2009012060A (es) Metodo de acupuntura y la aguja para llevar a cabo dicho método.
CN203898412U (zh) 一种骨科固定装置
DE60120917D1 (de) Kombinationspräparat zur krebstherapie
RU2003119967A (ru) Устройство и способ (варианты) нанесения покрытия из активного вещества на изделие, променение способа и изделие
DE602006009976D1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
FI3448430T3 (fi) Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
CN211325439U (zh) 一种超声引导下人体软组织压痛点针药合一、标本兼治系统
Gupta Transdermal drug delivery system
Lakhmani et al. Drug delivery through nails: An overview
RU2007111754A (ru) Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
CN2834538Y (zh) 治疗筋骨疼痛病的电极药贴
CN1175886C (zh) 一种外用止痛的药液及制备方法
RU2000104538A (ru) Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита